SPARC — 360° view

SPARC, a company in the Pharmaceuticals industry, reported revenue of ₹30 crore and a net loss of ₹25 crore for the September 2026 quarter.

SPARC (NSE: SPARC) closed at ₹190.16 on 20 Nov 2026, up 37.7% over the past year. Its market capitalisation is ₹6,171 crore and it trades at 3.8 times earnings.

Share price
₹190.16 (20 Nov 2026)
Market cap
₹6,171 Cr (20 Nov 2026)
P/E
3.75 (20 Nov 2026)
Revenue
₹30 Cr (September 2026 quarter)
Net profit
₹-25 Cr (September 2026 quarter)
ROCE
165% (FY26)
ROE
281% (FY26)
Book value
₹44.3 (FY26)
Dividend yield
0.00% (last 12 months to 20 Nov 2026)
52-week high / low
₹289.00 / ₹108.00 (20 Nov 2026)
1-year return
37.7% (to 20 Nov 2026)
Sector
Healthcare
Industry
Pharmaceuticals
Symbol
NSE: SPARC

Sun Pharma Advanced Research Company Ltd is engaged in the business of research and development (R&D) of pharmaceutical products.

Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.